Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

NISHIKAWA Tadaaki (Depertment of Medical Oncology)



Dr. NISHIKAWA's story

I have strong interest in the development of drug therapies for gynecologic cancer.

Research interests

Gynecologic Cancer

Professional Experiences

  • 2021- Present Staff Physician, Department of Medical Oncology, National Cancer Center Hospital
  • 2019- 2021 Staff Physician, Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2017-2019 Department of Gynecologic Oncology, Saitama Medical University International Medical Center
  • 2015-2017 Chief Resident, Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2010-2015 Department of Gynecologic Oncology, Saitama Medical University International Medical Center

Selected publications

  1. Suzuki M, Yagishita S, Sugihara K, Ogitani Y, Nishikawa T, Ohuchi M, et al. Visualization of intra-tumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. Clin Cancer Res. 2021:clincanres.0397.2021
  2. Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, et al. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precision Oncology. 2021(5):756-66.
  3. Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, et al. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Archiv : an international journal of pathology. 2021.
  4. Watanuki R, Shimomura A, Yazaki S, Noda-Narita S, Sumiyoshi-Okuma H, Nishikawa T, et al. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. Medicine (Baltimore). 2020;99(38):e22331.
  5. Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, et al. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology. 2020;98(10):699-705.
  6. Yano M, Asami Y, Nishikawa T, Yoshida S, Kamada K, Katoh T, et al. Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report. Medicine (Baltimore). 2018;97(43):e12937.
  7. Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, et al. PIK3CA mutation profiling in
    patients with breast cancer, using a highly sensitive detection system. Cancer Sci. 2018;109(8):2558-66.
  8. Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, et al. Phase 1 dose-escalation study of
    single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Sci. 2017;108(9):1834-42.
  9. Hirakawa A, Nishikawa T, Yonemori K, Shibata T, Nakamura K, Ando M, et al. Utility of Bayesian Single-Arm
    Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. Ther Innov Regul Sci. 2018;52(3):334-8.
  10. Nishikawa T, Hasegawa K, Yabuno A, Yoshida H, Yasuda M, Kozawa E, et al. Pazopanib as a second line
    treatment for uterine and ovarian carcinosarcoma: a single institutional study. J Gynecol Oncol. 2017;28(1):e25.